Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.36

-1.6%

1:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (1885)	10/25/2000 12:13:45 AM
From: seminole	Read Replies (1) of 52153

<<<In 96, when I first time learn about Iro PK data, at LA ASCO conference, I projected that it will fail as is. Fourth years later seams that I was correct. Also, I think that this PIII trial is desperate move.>>> LOL Four years ago you said, when the drug was in phase I, that it was too toxic. Now the drug is in phase III and this proves you were correct. LOL There will be many more "desperate" Phase III trials. There will be "desperate" drug approvals for many applications. And as I said before based upon your past and present analysis of irofulven, I understand why your bet on SUPG is speculative. We agree.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next